Free Trial

KalVista Pharmaceuticals (KALV) 10K Form and Latest SEC Filings 2026

KalVista Pharmaceuticals logo
$27.00 0.00 (0.00%)
As of 06/12/2026

Latest KalVista Pharmaceuticals SEC Filings & Recent Activity

KalVista Pharmaceuticals (NASDAQ:KALV) has submitted 502+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in KalVista Pharmaceuticals's financial statements. The most recent filing was a Form S-8 POS submitted on June 11, 2026.

Form 4
KalVista Pharmaceuticals, Inc. Reports Ownership Change on Jun. 11, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
KalVista Pharmaceuticals Files Current Report on Jun. 11, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
KalVista Pharmaceuticals Files Quarterly Report on May. 14, 2026

The 10-Q contains KalVista Pharmaceuticals's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

KalVista Pharmaceuticals SEC Filing History

Browse KalVista Pharmaceuticals' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
06/11/2026 3:37 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:38 PM
Fairey William (1727275) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:40 PM
KalVista Pharmaceuticals (1348911) Issuer
Pereira Brian JG (1298146) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:41 PM
KalVista Pharmaceuticals (1348911) Issuer
Stuart Nancy (1594774) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:44 PM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2026 3:47 PM
KalVista Pharmaceuticals (1348911) Filer
Form S-8 POS
06/11/2026 3:30 PM
KalVista Pharmaceuticals (1348911) Issuer
Reid Laurence (1492749) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:31 PM
Arif Bilal (1959750) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:31 PM
KalVista Pharmaceuticals (1348911) Filer
Form S-8 POS
06/11/2026 3:32 PM
KalVista Pharmaceuticals (1348911) Issuer
Sweeny Nicole (1827505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:33 PM
KalVista Pharmaceuticals (1348911) Issuer
Treanor Patrick (1929863) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:35 PM
KalVista Pharmaceuticals (1348911) Filer
Form S-8 POS
06/11/2026 3:36 PM
KalVista Pharmaceuticals (1348911) Filer
Form S-8 POS
06/11/2026 3:36 PM
KalVista Pharmaceuticals (1348911) Issuer
Sensenig Bethany (1899935) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2026 3:37 PM
KalVista Pharmaceuticals (1348911) Filer
Form S-8 POS
06/11/2026 3:13 PM
KalVista Pharmaceuticals (1348911) Filer
Form S-8 POS
06/11/2026 3:15 PM
KalVista Pharmaceuticals (1348911) Filer
Form S-8 POS
06/11/2026 3:17 PM
KalVista Pharmaceuticals (1348911) Filer
Form S-8 POS
06/11/2026 3:18 PM
KalVista Pharmaceuticals (1348911) Filer
Form S-8 POS
06/11/2026 3:19 PM
KalVista Pharmaceuticals (1348911) Filer
Form S-8 POS
06/11/2026 3:05 PM
KalVista Pharmaceuticals (1348911) Filer
Form POS AM
06/11/2026 9:25 AM
KalVista Pharmaceuticals (1348911) Subject
Nasdaq Stock Market LLC (1354457) Filed by
Form 25-NSE
06/11/2026 7:57 AM
KalVista Pharmaceuticals (1348911) Subject
Form SC 14D9/A
06/11/2026 8:03 AM
Chiesi Farmaceutici SpA (1464415) Filed by
KalVista Pharmaceuticals (1348911) Subject
Form SC TO-T/A
06/10/2026 4:03 PM
GLAZER CAPITAL, LLC (1076809) Filed by
KalVista Pharmaceuticals (1348911) Subject
Form SCHEDULE 13G
06/01/2026 8:05 AM
KalVista Pharmaceuticals (1348911) Subject
Form SC 14D9/A
06/01/2026 8:05 AM
Chiesi Farmaceutici SpA (1464415) Filed by
KalVista Pharmaceuticals (1348911) Subject
Form SC TO-T/A
05/29/2026 3:05 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2026 4:18 PM
KalVista Pharmaceuticals (1348911) Subject
Yea Christopher (1691102) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/27/2026 3:05 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2026 3:05 PM
KalVista Pharmaceuticals (1348911) Issuer
Sweeny Nicole (1827505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2026 3:05 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/26/2026 6:32 PM
KalVista Pharmaceuticals (1348911) Issuer
Piekos Brian (1815308) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/26/2026 6:33 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/26/2026 6:33 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/26/2026 6:34 PM
KalVista Pharmaceuticals (1348911) Issuer
Sweeny Nicole (1827505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/26/2026 6:35 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2026 3:46 PM
Frazier Life Sciences Public Fund, L.P. (1863769) Filed by
KalVista Pharmaceuticals (1348911) Subject
Form SCHEDULE 13D/A
05/19/2026 3:03 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2026 3:04 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/19/2026 3:05 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
SpaceX will crumble without these 5 companies (Ad)

The SpaceX IPO is drawing near, but the real opportunity may lie in 5 lesser-known companies providing the critical infrastructure SpaceX depends on to operate. Goldman Sachs and Morgan Stanley are reportedly already building positions in one of these names. Another is a resource miner that Elon Musk's broader empire - including Tesla - relies on. Lance Ippolito has detailed all five inside his free SpaceX Investing Blackbook.tc pixel

Download the free SpaceX Investing Blackbook before these names go mainstream
05/14/2026 3:05 PM
KalVista Pharmaceuticals (1348911) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/13/2026 3:40 PM
KalVista Pharmaceuticals (1348911) Subject
SILVERARC CAPITAL MANAGEMENT, LLC (1816307) Filed by
Form SCHEDULE 13G
05/13/2026 3:45 PM
KalVista Pharmaceuticals (1348911) Subject
Form SC 14D9
05/13/2026 6:22 AM
Chiesi Farmaceutici SpA (1464415) Filed by
KalVista Pharmaceuticals (1348911) Subject
Form SC TO-T
05/05/2026 3:51 PM
Chiesi Farmaceutici SpA (1464415) Filed by
KalVista Pharmaceuticals (1348911) Subject
Form SC TO-C
05/01/2026 4:32 PM
KalVista Pharmaceuticals (1348911) Subject
MILLENNIUM MANAGEMENT LLC (1273087) Filed by
Form SCHEDULE 13G/A
04/30/2026 3:35 PM
KalVista Pharmaceuticals (1348911) Filer
Form 10-KT/A
04/29/2026 7:30 AM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/20/2026 6:40 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 6:40 PM
KalVista Pharmaceuticals (1348911) Issuer
Piekos Brian (1815308) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 6:41 PM
KalVista Pharmaceuticals (1348911) Issuer
Sweeny Nicole (1827505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/20/2026 6:42 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/27/2026 4:50 PM
KalVista Pharmaceuticals (1348911) Issuer
Koh Bong Y (1615979) Reporting
Shah Nimish P (1698082) Reporting
Venrock Healthcare Capital Partners EG, L.P. (1808512) Reporting
Venrock Healthcare Capital Partners III, L.P. (1738048) Reporting
VHCP Co-Investment Holdings III, LLC (1750761) Reporting
VHCP Management EG, LLC (1808518) Reporting
VHCP Management III, LLC (1738053) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/25/2026 3:35 PM
KalVista Pharmaceuticals (1348911) Filer
Form 10-KT
03/25/2026 6:16 AM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/10/2026 5:47 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 6:44 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 6:42 PM
KalVista Pharmaceuticals (1348911) Issuer
Piekos Brian (1815308) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 6:42 PM
KalVista Pharmaceuticals (1348911) Issuer
Sweeny Nicole (1827505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 6:43 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 6:44 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 6:44 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 6:44 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 6:45 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/26/2026 4:00 PM
KalVista Pharmaceuticals (1348911) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
01/21/2026 3:09 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:10 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:10 PM
KalVista Pharmaceuticals (1348911) Issuer
Piekos Brian (1815308) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:11 PM
KalVista Pharmaceuticals (1348911) Issuer
Sweeny Nicole (1827505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:11 PM
Arif Bilal (1959750) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2026 5:03 PM
KalVista Pharmaceuticals (1348911) Subject
Point72 Asset Management, L.P. (1603466) Filed by
Form SCHEDULE 13G/A
01/12/2026 5:34 PM
KalVista Pharmaceuticals (1348911) Subject
Point72 Asset Management, L.P. (1603466) Filed by
Form SCHEDULE 13G
01/08/2026 3:47 PM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/30/2025 3:28 PM
KalVista Pharmaceuticals (1348911) Subject
MILLENNIUM MANAGEMENT LLC (1273087) Filed by
Form SCHEDULE 13G/A
12/09/2025 5:16 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/04/2025 3:02 PM
KalVista Pharmaceuticals (1348911) Issuer
Sweeny Nicole (1827505) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/26/2025 5:49 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/26/2025 5:50 PM
KalVista Pharmaceuticals (1348911) Issuer
Piekos Brian (1815308) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/26/2025 5:46 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/26/2025 5:47 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/21/2025 3:07 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:11 PM
Audhya Paul K. (1860131) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:11 PM
KalVista Pharmaceuticals (1348911) Issuer
Yea Christopher (1691102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:13 PM
KalVista Pharmaceuticals (1348911) Issuer
Palleiko Benjamin L (1366244) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/10/2025 3:45 PM
KalVista Pharmaceuticals (1348911) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/04/2025 4:21 PM
Frazier Life Sciences Public Fund, L.P. (1863769) Filed by
KalVista Pharmaceuticals (1348911) Subject
Form SCHEDULE 13D/A
10/08/2025 5:58 PM
Arif Bilal (1959750) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 3
Initial statement of beneficial ownership of securities  
10/08/2025 5:59 PM
Arif Bilal (1959750) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/06/2025 6:15 AM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/02/2025 5:27 PM
KalVista Pharmaceuticals (1348911) Issuer
Sensenig Bethany (1899935) Reporting
Form 3
Initial statement of beneficial ownership of securities  
SpaceX IPO hides a much bigger story (Ad)

The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.tc pixel

Click here to see the details before the crowd catches on
10/02/2025 5:28 PM
KalVista Pharmaceuticals (1348911) Issuer
Sensenig Bethany (1899935) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 5:28 PM
KalVista Pharmaceuticals (1348911) Issuer
Unkart Edward W (1306267) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 5:29 PM
Fairey William (1727275) Reporting
KalVista Pharmaceuticals (1348911) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 5:30 PM
KalVista Pharmaceuticals (1348911) Issuer
Treanor Patrick (1929863) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 5:30 PM
KalVista Pharmaceuticals (1348911) Issuer
Stuart Nancy (1594774) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 5:31 PM
KalVista Pharmaceuticals (1348911) Issuer
Pereira Brian JG (1298146) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/02/2025 6:15 AM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/29/2025 3:27 PM
KalVista Pharmaceuticals (1348911) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/11/2025 6:45 AM
KalVista Pharmaceuticals (1348911) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

KalVista Pharmaceuticals SEC Filings - Frequently Asked Questions

KalVista Pharmaceuticals (KALV) has submitted 502+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

KalVista Pharmaceuticals's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on KalVista Pharmaceuticals's financial statements page.

The most recent filing was a Form S-8 POS submitted on June 11, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:KALV) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners